Pomalidomide 4'-PEG3-azide

Background Introduction

Pomalidomide 4'-PEG3-azide is a specialized E3 ligase ligand-linker conjugate frequently used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). By fusing the immunomodulatory drug pomalidomide, a CRBN (Cereblon) E3 ligase recruiter, with a PEG3 linker terminating in an azide group, this product provides high utility and versatility in targeted protein degradation research and drug discovery.

Mechanism

The mechanism of action for Pomalidomide 4'-PEG3-azide centers on its bifunctional properties. The pomalidomide moiety selectively binds the CRBN E3 ubiquitin ligase complex, while the PEG3-azide linker enables bio-orthogonal click chemistry, facilitating conjugation with various ligands that target proteins of interest. Once incorporated into a PROTAC molecule, this conjugate enables the proximity-induced ubiquitination of the target protein, leading to its recognition and subsequent degradation via the proteasome pathway.

Applications

Pomalidomide 4'-PEG3-azide is primarily used in the synthesis of CRBN-based PROTACs and molecular glues for targeted protein degradation. The terminal azide allows for efficient, modular assembly of PROTACs using click chemistry, accelerating the rapid design of custom degraders against oncogenic proteins, transcription factors, or other disease-related targets. Additionally, it is valuable for chemical biology studies, drug screening platforms, and research in cellular signaling pathways where precise protein knockdown is desired.

The E3 Ligase Ligand-Linker Conjugate, Pomalidomide 4'-PEG3-azide, serves as a crucial component in the design of PROTACs, facilitating targeted protein degradation by linking the E3 ligase to specific protein targets. This molecule's unique structure enhances its versatility and effectiveness in various research applications, as detailed in the following descriptions of its linker, ligand, and reactive site.

Linker: The linker in this molecule is a PEG3 (polyethylene glycol) chain, providing moderate length and flexibility. This characteristic aids in bridging the ligand and the target protein efficiently, while its non-cleavable nature ensures stability and persistence in cellular environments.

Ligand: The ligand component is derived from pomalidomide, a thalidomide analogue known for its high affinity to the CRBN E3 ligase. Its structural features enable selective binding, making it an effective tool for recruiting the E3 ligase to the target protein.

Reactive Site: The azide functional group in this molecule serves as the reactive site, capable of coupling with alkyne-functionalized target protein ligands through click chemistry reactions. This site offers a robust and efficient conjugation mechanism, facilitating the formation of stable PROTAC complexes.

Recommended Target Protein Ligand: A suitable warhead for this conjugate is an alkyne-functionalized small molecule, providing a complementary reactive partner for the azide group. This combination allows for bio-orthogonal click chemistry reactions, ensuring precise and efficient targeting of proteins for degradation. The application of such warheads in PROTACs can significantly enhance the specificity and efficacy of protein degradation studies.